EUVIMEDEUVIMED entdecken
Crossref

Challenges of a tailored immunohistochemistry algorithm for uterine leiomyosarcoma: an integrated analysis of leiomyomas with bizarre nuclei and fumarate hydratase ( FH) deficiency

Catarina Alves-Vale iD, Nathalène Truffaux, Valérie Velasco, Rihab Azmani, Melissa Alamé, Flora Rebier, Laetitia Mayeur, Yanick Leger, Isabelle Hostein, Isabelle Soubeyran, Larry Blanchard, Estelle Marion und 7 weitere

Histopathology · 2025

DOI: 10.1111/his.15420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, 2025. Verfasst von Catarina Alves-Vale und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, CUF Descobertas Hospital, Lisbon, Portugal. Hauptthemen laut MEDLINE: Uterine Neoplasms, Algorithms, Leiomyosarcoma, Fumarate Hydratase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Leiomyomas (LM) are the most common uterine mesenchymal neoplasms and encompass a variety of histological subtypes. Bizarre nuclei are described in both leiomyomas with bizarre nuclei (LM‐BN) and fumarate hydratase‐deficient leiomyomas (FH‐LM), which raise diagnostic concerns regarding leiomyosarcoma (LMS). Recently, an immunohistochemical algorithm to support the diagnosis of LMS based on the genomic landscape of these neoplasms was proposed. This study aimed to evaluate the algorithm's accuracy in distinguishing LM‐BN and FH‐LM from LMS. Methods and Results We collected 68 LM (29 LM‐BN, 30 FH‐LM, and 9 LM) and 9 LMS, along with clinicopathological and molecular data. An immunohistochemical panel comprising p53, Rb, PTEN, ATRX, DAXX, and MDM2 was applied. Nine cases were non‐interpretable due to fixation issues. The algorithm demonstrated 100% accuracy for LM without bizarre nuclei (9/9) and for nonmyxoid LMS (5/5). Notably, 28.6% (14/49) of LM‐BN and FH‐LM exhibited at least two abnormalities, leading to potential misclassification as LMS. However, their clinical course, morphology, and genomic profile supported a benign diagnosis. Frequent alterations included Rb (20/49; 40.8%) and p53 (19/49; 38.8%), particularly in bizarre cells, while no abnormal staining was observed for ATRX, DAXX, or MDM2.

Conclusion

The proposed algorithm has limitations in differentiating LMS from LM‐BN and FH‐LM, misclassifying 28.6% of the latter. Accurate interpretation requires proper internal controls, particularly for markers whose loss of expression favours malignancy. Morphology remains central for diagnosis, although integration of molecular data may provide additional insights for a definitive classification in challenging cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine NeoplasmsAlgorithmsLeiomyosarcomaFumarate HydrataseBiomarkers, TumorLeiomyomaHumansFemaleImmunohistochemistryMiddle AgedAdultAgedCell NucleusDiagnosis, Differential

Stichwörter der Autor:innen

algorithmfumarate hydratase‐deficient leiomyomaimmunohistochemistryleiomyoma with bizarre nuclei

Substanzen

Fumarate HydrataseBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, CUF Descobertas Hospital, Lisbon, Portugal.
  • Department of Biopathology, Institut Bergonié, Bordeaux, France.
  • Department of Bioinformatics, Institut Bergonié, Bordeaux, France.
  • Department of Pathology, Cliniques Universitaires de St Luc, Bruxelles, Belgique, Belgium.
  • University of Bordeaux, Talence, France.
  • Bordeaux Institute of Oncology, BRIC, INSERM, Bordeaux University, Bergonié Institute, Talence, France.

ORCID-Profile: Catarina Alves-Vale, François Le Loarer, Mojgan Devouassoux-Shisheboran, Sabrina Croce

Zitieren

APA

Alves-Vale, C., Truffaux, N., Velasco, V., Azmani, R., Alamé, M., Rebier, F., Mayeur, L., Leger, Y., Hostein, I., Soubeyran, I., Blanchard, L., Marion, E., Fontanges, Q., Le Loarer, F., Averous, G., Genestie, C., Arnould, L., Devouassoux-Shisheboran, M., & Croce, S. (2025). Challenges of a tailored immunohistochemistry algorithm for uterine leiomyosarcoma: an integrated analysis of leiomyomas with bizarre nuclei and fumarate hydratase ( FH) deficiency. Histopathology. https://doi.org/10.1111/his.15420

Vancouver

Alves-Vale C, Truffaux N, Velasco V, Azmani R, Alamé M, Rebier F, et al. Challenges of a tailored immunohistochemistry algorithm for uterine leiomyosarcoma: an integrated analysis of leiomyomas with bizarre nuclei and fumarate hydratase ( FH) deficiency. Histopathology. 2025. doi:10.1111/his.15420

BibTeX
@article{AlvesVale2025,
  author = {Alves-Vale, Catarina and Truffaux, Nathalène and Velasco, Valérie and Azmani, Rihab and Alamé, Melissa and Rebier, Flora and Mayeur, Laetitia and Leger, Yanick and Hostein, Isabelle and Soubeyran, Isabelle and Blanchard, Larry and Marion, Estelle and Fontanges, Quitterie and Le Loarer, François and Averous, Gerlinde and Genestie, Catherine and Arnould, Laurent and Devouassoux-Shisheboran, Mojgan and Croce, Sabrina},
  title = {Challenges of a tailored immunohistochemistry algorithm for uterine leiomyosarcoma: an integrated analysis of leiomyomas with bizarre nuclei and fumarate hydratase ( FH) deficiency},
  journal = {Histopathology},
  year = {2025},
  doi = {10.1111/his.15420}
}
Kostenlos starten →